Results 211 to 220 of about 88,182,083 (298)

"[I]t will be like a full course meal": healthcare worker perspectives on strategies to optimize integration of PrEP into medication for opioid use disorder and needle and syringe exchange programs for people who use drugs in Kampala, Uganda. [PDF]

Addict Sci Clin Pract
Chhun N, Kamusiime B, Nalumansi A, Twesige CC, Nalukwago GK, Kasiita V, Mudiope P, Kansiime R, Muwonge TR, Kyambadde P, Kadama H, Glick S, Lambdin B, Heffron R, Mujugira A, Beima-Sofie K.   +15 more
europepmc   +1 more source

Brain reward function in young people with cannabis use disorder: A functional magnetic resonance imaging study

Addiction, EarlyView.
Abstract Background and Aims Cannabis use disorder (CUD) affects ~50 million people globally. Neuroscientific theories suggest that a blunted neural response to non‐drug rewards is a hallmark of substance use disorders; however, this remains untested in CUD. The current study tested whether brain reward system responses to the anticipation and feedback
Martine Skumlien, Lisa‐Marie Greenwood, Arush Honnedevasthana Arun, Isabella Goodwin, Anastasia Paloubis, Tribikram Thapa Rana, Marianna Quinones Valera, Eugene McTavish, Gabrielle Abbott, Suraya Dunsford, Antonio Verdejo‐Garcia, Jessica Ramamurthy, Mark M. Schira, Nadia Solowij, Chao Suo, Valentina Lorenzetti   +15 more
wiley   +1 more source

Beyond abstinence: Redefining success in cannabis use disorder treatment

Addiction, EarlyView.
Abstract Background Over two decades of pharmacotherapy research has yet to yield a consistently effective medication for cannabis use disorder (CUD), in part because clinical trials have frequently prioritized abstinence as a primary or key endpoint.
Tobias B. Atkin, Frances R. Levin, John Mariani, Christina A. Brezing   +3 more
wiley   +1 more source

Cannabis use disorder in patients prescribed medical cannabis—Should we consider prescription cannabis use disorder as a new diagnostic condition?

Addiction, EarlyView.
Abstract Background and Aims The introduction of prescribed medical cannabis in many parts of the world raises issues regarding how we conceptualise Cannabis Use Disorders (CUD). The Diagnostic Statistical Manual Version 5 (DSM5) provides a framework for ‘Prescription Cannabis Use Disorder’ (Pr‐CUD) when a person is using medical cannabis only‐as ...
Nicholas Lintzeris, Llewellyn Mills
wiley   +1 more source

"Trust and suspicion" client and provider perspectives on the acceptability of medication for opioid use disorder among people who inject drugs in Kampala, Uganda. [PDF]

Harm Reduct J
Mudiope P, Nanyeenya N, Okurut S, Twimukye A, Simon K, Mutamba Byamah B, Nangendo J, Alamo S, Makumbi F, Wanyenze R, Matovu JKB.   +10 more
europepmc   +1 more source

People experiencing homelessness and their experiences with substance use services for alcohol treatment in England: Journey mapping based on semi‐structured interviews

Addiction, EarlyView.
Abstract Background and aims Alcohol consumption at high levels is common among people experiencing homelessness and contributes to inequalities. In relative terms these individuals are underrepresented in substance use services. This study captured common trajectories and identified barriers and facilitators to accessing treatment among a group of ...
Vera Helen Buss, Jamie Brown, Melissa Oldham, Sarah E. Jackson, Lion Shahab, Dimitra Kale, Sharon Cox   +6 more
wiley   +1 more source

Predicting treatment retention in medication for opioid use disorder: a machine learning approach using NLP and LLM-derived clinical features. [PDF]

J Am Med Inform Assoc
Nateghi Haredasht F, Lopez I, Tate S, Ashtari P, Chan MM, Kulkarni D, Chen CA, Vangala M, Griffith K, Bunning B, Miner AS, Hernandez-Boussard T, Humphreys K, Lembke A, Vance LA, Chen JH.   +15 more
europepmc   +1 more source

Prescribed pharmaceutical alternatives initiative coinciding with reductions in unregulated street opioid use among young people who use drugs: An interrupted time series analysis

Addiction, EarlyView.
Abstract Background and aims In British Columbia, Canada, an initiative was implemented in 2020 to reduce overdose mortality by prescribing pharmaceutical opioids (primarily hydromorphone) as a substitute for the toxic unregulated drug supply. This study estimated changes in the level and trend of unregulated opioid use and non‐prescribed hydromorphone
Erica McAdam, Mohammad Karamouzian, Michael John Milloy, Carmen Verdicchio, Eric C. Sayre, Kanna Hayashi, Thomas Kerr, Kora DeBeck   +7 more
wiley   +1 more source

Prescribed alternative stimulants among people who use unregulated stimulants: Examining the association between maximum dose reached and medication discontinuation in the first 3 years of implementation in British Columbia, Canada

Addiction, EarlyView.
Abstract Background and aims In 2020, British Columbia (BC), Canada, introduced ‘Prescribed Alternatives’ (PA) as an approach to offering regulated substances to people accessing the unregulated supply. This study aimed to estimate and compare prescribing characteristics of dextroamphetamine and methylphenidate stimulant PAs in BC, to estimate ...
Bin Zhao, Kevin Hu, Roshni Desai, Shania Au, Kali‐olt Sedgemore, Vitor Tardelli, Addie Carter, Paxton Bach, Christian Schutz, Amanda Slaunwhite, Alexis Crabtree, Heather Palis   +11 more
wiley   +1 more source